[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"drug-interactions\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:drug-interactions":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,52,83,114,143],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100053765","phase-4-ldl-c-optimization-using-inclisiran-in-patients-in-which-drug-drug-interactions-limit-ldl-lowering-100053765",false,"NCT06865885","LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering","Study of Optimal LDL-C Value Enhancement With Inclisiran in Patients With Multiple Comorbidities in Which There Are Drug-Drug Interactions Limiting LDL-C Lowering","SOLVE-LDL-C","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form.\n* Stated willingness to comply with all study procedures and availability for the duration of the study, including potential randomization to injections.\n* Age \\>18 and \\\u003C85 years and able to provide self-consent.\n* Taking five or more prescription drugs at the time of enrollment, of any type.\n* Meets at least one of the following criteria:\n\n  * Elevated 10-year ASCVD risk score ≥7.5% (based on the ACC\u002FAHA ASCVD Risk Estimator Plus tool).\n  * Evidence of subclinical atherosclerosis including:\n\nCalcification in any vascular bed, including coronary arteries and aorta. Calcification of cardiac valves. Breast calcification. Carotid plaque that is not hemodynamically significant.\n\no Type II diabetes on a stable medical regimen with HbA1c \\\u003C8.5%. Per American Diabetes Association guidelines, patients with Type II diabetes aged 40-75 years should be on a moderate-intensity statin.\n\nPatients with documented partial or complete statin intolerance are eligible for enrollment.\n\n* On maximally tolerated statin therapy (which can be no statin for patients with documented intolerance) and have suboptimal LDL levels:\n\n  * For patients with Type II diabetes: LDL \\>70 mg\u002FdL or non-HDL \\>120 mg\u002FdL.\n  * For other patients: LDL \\>90 mg\u002FdL or non-HDL \\>120 mg\u002FdL.\n* Willing to adhere to the randomized study regimen, including subcutaneous injection of inclisiran.\n* Agreement to adhere to lifestyle considerations (see Section 5.3) throughout the study duration.\n\nExclusion Criteria:\n\n* Prior or current use of inclisiran.\n* Known hypersensitivity or allergy to inclisiran or its components.\n* Active liver disease or unexplained persistent elevations in liver enzymes (ALT or AST \\>3x upper limit of normal).\n* History of rhabdomyolysis or severe muscle-related statin intolerance.\n* Uncontrolled diabetes (HbA1c \\>8.5%).\n* Active malignancy requiring systemic therapy.\n* Recent major cardiovascular event (myocardial infarction, stroke, or hospitalization for unstable angina) within the past 3 months.\n* History of organ transplant other than solid-organ transplant.\n* Pregnancy or breastfeeding.\n* Any condition that, in the opinion of the investigator, would make participation unsafe or interfere with study procedures.","ALL","18 Years","85 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","Drug-drug interactions often limit statin optimization in a population of patients prescribed cytochrome P3A4 inhibitors, which include immunosuppressive agents, protease inhibitors, and antifungals. These patients frequently have autoimmune conditions or rheumatologic disorders that require complex drug regimens and are often on low-dose statin therapy or no statin at all, resulting in suboptimal LDL levels despite increased cardiovascular (CV) risk.\n\nThere is an unmet clinical need to improve LDL levels in this vulnerable patient population, which faces increased CV risk due to underlying conditions that also contribute to polypharmacy and multiple drug-drug interactions. This study is a randomized, open-label trial evaluating subcutaneous inclisiran plus standard of care for LDL-C lowering in high-risk primary prevention patients with multiple comorbidities (e.g., Type II diabetes, liver disease, chronic kidney disease, autoimmune disease, solid-organ transplant) who are taking five or more medications in which drug-drug interactions prevent optimization of statin therapy.",[28,29,30,31],"Drug Interactions","Primary Prevention","Cardiometabolic Syndrome","LDL-Cholersterol Lowering",[33,34,35,36,37,38],"Statin intolerance","drug drug interaction","inclisiran","LDL-Cholesterol","polypharmacy","multiple comorbidities","RECRUITING","2026-07-10",{"date":42,"type":43},"2026-07-13","ACTUAL",{"date":45,"type":43},"2025-04-02",{"date":47,"type":22},"2027-03-31",{"name":49,"class":50},"University of California, San Diego","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":51},"100574273","phase-1-opioid-drug-interaction-study-100574273","NCT06757140","Opioid Drug Interaction Study","Opioid Drug Interactions: Safety, Abuse Potential and Pharmacokinetic Effects","Inclusion Criteria:\n\n* English-speaking and literate participants, able to understand and sign Informed Consent Document\n* ages 18 to 55 years old inclusive\n* BMI of greater than\u002Fequal to 17 and approximately less than or equal to 30\n* self-reported opioid use\n* self-reported sedative-like drug use\n* women of childbearing potential must not be pregnant or breastfeeding at screening and be using an effective form of contraception throughout study participation\n* otherwise healthy as determined by the medical\u002Fresearch team based on medical history, physical examination, vital signs, laboratory chemistries (blood chemistry with liver function tests and hematology, urinalysis and microscopic evaluation, 12-lead electrocardiogram)\n* willing and able to comply with all testing requirements defined in the protocol\n* adequate venous access (determined by RN) for pharmacokinetic blood draws\n\nExclusion Criteria:\n\n* physical dependence on alcohol, opioids, benzodiazepines or sedative\u002Fhypnotics requiring medical management\u002Fdetoxification\n* seeking treatment for opioid or any other drug use\n* acute medical problem (e.g., infection) or chronic medical problem requiring daily medication or ongoing medical care (e.g., hypertension, cardiovascular disease, diabetes, respiratory disorders \\[e.g., asthma, COPD\\])\n* clinically significant abnormal ECG (as determined by study physician\u002Fcardiologist)\n* clinically significant abnormal laboratory findings (e.g., liver function tests greater than 3x the upper limits of normal range)\n* current or past history of major psychiatric disorder that would limit ability to participate in the study (e.g., bipolar disorder).\n* recent use of CYP2C9, CYP2D6 and CYP3A4 inhibitor or inducer that is long-acting and not amenable to a wash-out period after enrollment\n* known hypersensitivity to any of the study drugs\n* currently pregnant or breastfeeding\n* currently under parole or probation with urine testing requirements","55 Years",{"count":61,"type":22},25,[63,64],"PHASE1","PHASE2","This study will examine the effects of doses of opioid\u002Fplacebo and doses of alprazolam\u002Fplacebo, alone and in combination. The primary outcomes are pharmacodynamic measures (subjective ratings of drug liking and other abuse-related effects; physiological outcomes) and pharmacokinetic outcomes (from blood samples) to determine the interaction effects of these compounds.",[28,67],"Drug Kinetics",[69,70,71,72,73],"inpatient study","opioids","opiates","sedatives","opioid misuse","2026-05-13",{"date":76,"type":43},"2026-05-14",{"date":78,"type":43},"2025-04-01",{"date":80,"type":22},"2029-06-01",{"name":82,"class":50},"Shanna Babalonis, PhD",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":90,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":94,"conditions":95,"keywords":100,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":51},"100528356","telecommunication-technology-based-online-survey-100528356","NCT06159699","Telecommunication Technology-based Online Survey","New Challenges for the Population on the Path to Achieving Active Longevity: an Online Survey of Respondents Using Telecommunication Technologies","Inclusion Criteria:\n\n* age of 18 years and older\n* signing the informed concent form online\n* completion of the entire questionnaire\n\nExclusion Criteria:\n\n* age under 18 years\n* refuse to sign the informed concent form",true,{"count":92,"type":22},2000,"OBSERVATIONAL","The aim of this study is to identify and assess new health-associated risk factors, including clinical-pharmacological risk factors. The cohort is built using telecommunication approaches. The associations between clinical-pharmacological, social, demographic, behavioral, and environmental characteristics will be assessed. The continuous depersonalized online survey is performed using the original informational resources in the form of specially designed web-site aimed at identification and assessment of population-based pharmacotherapy patterns including characteristics of self-medication, biologically active food supplement intake, polypharmacy, and adverse drug-drug interactions in the people residing in the ecological conditions of various regions of the country. The invitations to participate in the online survey are sent via the SMS messages using the SMS-Target tool provided by OOO T2 Mobile Company. The survey is performed online at www.zdorov.tpu.ru and www.zdorov.expert both specifically designed for questionnaire publication and data accumulation.",[96,97,28,98,99],"Risk Factors","Polypharmacy","Self Medication","COVID-19",[97,101,98,99,102,103,104],"Potential Drug-Drug Interactions","Medical Imaging","Environmental Risk Factors","Protracted Low-Dose-Rate Radiation Exposure","2026-01-23",{"date":107,"type":43},"2026-01-27",{"date":109,"type":43},"2022-12-02",{"date":111,"type":22},"2028-12-31",{"name":113,"class":50},"Tomsk National Research Medical Center of the Russian Academy of Sciences",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":23,"phases":124,"briefSummary":126,"conditions":127,"keywords":129,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":51},"100593935","early-phase-1-relationship-between-remimazolam-and-etomidate-in-induction-of-general-anesthesia-100593935","NCT07012902","Relationship Between Remimazolam and Etomidate in Induction of General Anesthesia","The Interaction Between Remimazolam and Etomidate During Induction of General Anesthesia Was Studied by Isoradiometric Analysis","Inclusion Criteria:\n\n1. Both sexes\n2. aged 18-60 yr\n3. ASA physical status I-II\n4. BIM: 18-28kg\u002Fm²\n\nExclusion Criteria:\n\n1. allergic to remimazolam and etomidate\n2. in pregnancy or lactation\n3. serious cardiovascular diseases, long-term alcoholism\n4. used sedative drugs or opioids within 24 hours\n5. severe mental illness and myasthenia gravis -","60 Years",{"count":123,"type":22},125,[125],"EARLY_PHASE1","In modern anesthesia practice, anesthesiologists often need to choose a combination of multiple drugs according to the specific conditions and surgical needs of patients, which can not only achieve more fine anesthesia management, but also improve perioperative safety and patient comfort. In clinical practice, anesthesiologists will use etomidate combined with a small dose of remimazolam for anesthesia induction to obtain more stable hemodynamics, prevent intraoperative awareness, and relieve anxiety.However, what is the best dose ratio of etomidate combined with remimazolam, the current literature does not give clear indicators.",[128,28],"Induction Anesthesia",[130,131,132],"Isoradiation analysis","etomidate","remimazolam","NOT_YET_RECRUITING","2025-06-08",{"date":136,"type":43},"2025-06-10",{"date":138,"type":22},"2025-06-12",{"date":140,"type":22},"2025-07-19",{"name":142,"class":50},"Second Hospital of Shanxi Medical University",{"id":144,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":145,"targetDuration":4,"studyType":23,"phases":146,"briefSummary":26,"conditions":147,"keywords":148,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":51},"100582636",{"count":21,"type":22},[25],[28,29,30,31],[33,34,35,36,37,38],"2025-04-08",{"date":151,"type":43},"2025-04-11",{"date":153,"type":43},"2025-04-03",{"date":155,"type":22},"2026-12-31",{"name":49,"class":50}]